Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHI-902
- Development stage
- Discontinued
- Lead developer
- C³ Cannabinoid Compound
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CHI-902 is a standardized cannabidiol (CBD) oil formulation developed by Canopy Growth Corporation for the treatment of Social Anxiety Disorder (SAD). It consists of a cannabis-derived CBD extract dissolved in a medium-chain triglyceride (MCT) oil vehicle for oral administration. The drug's therapeutic potential in anxiety is thought to be mediated through its interaction with the endocannabinoid system, specifically by modulating cannabinoid receptors and inhibiting the enzyme fatty acid amide hydrolase (FAAH), as well as acting as an agonist at the 5-HT1A serotonin receptor. CHI-902 has been evaluated in a Phase IIb randomized, double-blind, placebo-controlled clinical trial to determine its efficacy in reducing anxiety symptoms and its effect on peripheral endocannabinoid levels.
- Brand names
- CHI-902CHI902CHI 902
- Other names
- CBD oilcannabidiol oil
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))FAAHCNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on CHI-902.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHI-902.